Search for: "Ventures Acquisition Company" Results 101 - 120 of 1,641
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
1 Aug 2023, 8:00 am by Sherica Celine
Venture Financing Overview Learn more about venture capital, which is an important source of money for start-up companies that do not have access to the capital markets. [read post]
29 Jul 2023, 2:17 am by InhouseBlog
Mergers and Acquisitions Guide for In-House Counsel – Intro This mergers and acquisitions guide provides in-house counsel with an overview of the process of selling a privately-held company in an M&A transaction and some of the significant deal points typically negotiated by the parties. [read post]
28 Jul 2023, 6:30 am
Securities and Exchange Commission, on Thursday, July 27, 2023 Tags: Cybersecurity, Disclosure, ESG, Monetary policy, Risk, SEC enforcement Statement by Chair Gensler on Public Company Cybersecurity Disclosures Posted by Gary Gensler, U.S. [read post]
28 Jul 2023, 6:30 am
Securities and Exchange Commission, on Thursday, July 27, 2023 Tags: Cybersecurity, Disclosure, ESG, Monetary policy, Risk, SEC enforcement Statement by Chair Gensler on Public Company Cybersecurity Disclosures Posted by Gary Gensler, U.S. [read post]
25 Jul 2023, 10:43 am by Rob Robinson
The acquisition aims to expand and speed up Thomson Reuters’ generative AI solutions, reshaping how professionals work. [read post]
25 Jul 2023, 3:44 am by Greg Lambert and Marlene Gebauer
Casetext’s acquisition by Thomson Reuters illustrates the present-day limitations of large language models trained primarily on case law. [read post]
20 Jul 2023, 7:20 am
             Has anyone empirically proven that a merger or acquisition enhances consumer welfare rather than the acquiring company's profitability? [read post]
20 Jul 2023, 7:20 am
             Has anyone empirically proven that a merger or acquisition enhances consumer welfare rather than the acquiring company's profitability? [read post]
19 Jul 2023, 5:06 am by Amber Walsh
Thoma Bravo’s investment in Bluesight is intended to help support the company’s acquisition of Medacist. [read post]
19 Jul 2023, 5:06 am by Robert Kurtz
Thoma Bravo’s investment in Bluesight is intended to help support the company’s acquisition of Medacist. [read post]
13 Jul 2023, 7:00 am by Katherine Oberlies
Securities and Exchange Commission (“SEC”) issued an order against Insight Venture Management LLC (“Insight”). [read post]
30 Jun 2023, 12:04 pm by Cannabis Law Group
Joint ventures can help bolster profits and reduce costs for both operations – without having to endure the hassle and legal headaches of a formalized acquisition. [read post]
28 Jun 2023, 5:46 am by Bob Ambrogi
This is a company that, through acquisitions, brought on products like Westlaw and Practical Law Company. [read post]
21 Jun 2023, 9:05 pm by renholding
Our paper aims to analyze the dynamics of the IPO valuation premium before 2000 and after 2000, thereby generating new insights into the IPO valuation premium and the reasons why more companies have exited through acquisitions than IPOs since 2000. [read post]
12 Jun 2023, 4:02 pm by Stoltmann Law
(“Matrix”), a leading independent investment bank, announces that it served as lead advisor on Apollo Veterinary Medical Hospitals and AVMH Ventures’ (“Apollo” or the “Company”) recapitalization and acquisition of a multi-state portfolio of Pet Supplies Plus (“PSP”) [...] [read post]
12 Jun 2023, 2:19 pm by Stoltmann Law
(“Matrix”), a leading independent investment bank, announces that it served as lead advisor on Apollo Veterinary Medical Hospitals and AVMH Ventures’ (“Apollo” or the “Company”) recapitalization and acquisition of a multi-state portfolio of Pet Supplies Plus (“PSP”) [...] [read post]
9 Jun 2023, 8:36 am by Ashwin Varma
The challenge represents a landmark in the history of pharmaceutical-industry antitrust enforcement, as the industry has largely been given license to engage in permissive mergers and acquisitions of smaller companies without challenge. [read post]
9 Jun 2023, 8:36 am by Ashwin Varma
The challenge represents a landmark in the history of pharmaceutical-industry antitrust enforcement, as the industry has largely been given license to engage in permissive mergers and acquisitions of smaller companies without challenge. [read post]